Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.
作者信息
Weiner H L
出版信息
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3333-5. doi: 10.1073/pnas.96.7.3333.
Abstract
摘要
相似文献
1
Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.用共聚物1进行口服耐受治疗多发性硬化症。
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3333-5. doi: 10.1073/pnas.96.7.3333.
2
Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.醋酸格拉替雷（考帕松）可诱导多发性硬化症患者产生退化性、Th2极化免疫反应。
J Clin Invest. 2000 Apr;105(7):967-76. doi: 10.1172/JCI8970.
3
Recent insights into the mechanism of action of glatiramer acetate.对醋酸格拉替雷作用机制的最新认识。
J Neuroimmunol. 2011 Jun;235(1-2):9-17. doi: 10.1016/j.jneuroim.2011.01.009. Epub 2011 Mar 13.
4
The use of glatiramer acetate in the treatment of multiple sclerosis.醋酸格拉替雷在多发性硬化症治疗中的应用。
Adv Neurol. 2006;98:273-92.
5
Glatiramer acetate (Copaxone) therapy for multiple sclerosis.醋酸格拉替雷（考帕松）治疗多发性硬化症。
Pharmacol Ther. 2003 May;98(2):245-55. doi: 10.1016/s0163-7258(03)00036-6.
6
Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients.源自醋酸格拉替雷治疗的多发性硬化症患者的T细胞系的特征分析
J Neuroimmunol. 2000 Aug 1;108(1-2):201-6. doi: 10.1016/s0165-5728(00)00263-0.
7
Glatiramer: a second look. With longer follow-up: still no proven benefit in multiple sclerosis.格拉替雷：再审视。随着随访时间延长：对多发性硬化症仍无已证实的益处。
Prescrire Int. 2009 Dec;18(104):252.
8
Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1.口服共聚物1对实验性自身免疫性脑脊髓炎的免疫调节作用
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3842-7. doi: 10.1073/pnas.96.7.3842.
9
Glatiramer acetate in the treatment of multiple sclerosis.醋酸格拉替雷治疗多发性硬化症
Expert Opin Pharmacother. 2001 Jul;2(7):1149-65. doi: 10.1517/14656566.2.7.1149.
10
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.醋酸格拉替雷（考帕松）的长期使用耐受性良好，并能维持其对多发性硬化症复发率和残疾程度的临床疗效。共聚物1多发性硬化症研究组。
Neurology. 1998 Mar;50(3):701-8. doi: 10.1212/wnl.50.3.701.
引用本文的文献
1
Glatiramer acetate attenuates the activation of CD4 T cells by modulating STAT1 and -3 signaling in glia.醋酸格拉替雷通过调节神经胶质细胞中 STAT1 和 -3 信号转导来抑制 CD4 T 细胞的激活。
Sci Rep. 2017 Jan 17;7:40484. doi: 10.1038/srep40484.
2
Induction of mucosal tolerance in SLE: a sniff or a sip away from ameliorating lupus?系统性红斑狼疮中黏膜耐受的诱导：通过嗅闻或啜饮就能改善狼疮吗？
Clin Immunol. 2009 Feb;130(2):111-22. doi: 10.1016/j.clim.2008.08.028. Epub 2008 Oct 19.
3
Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.作为选择性免疫治疗基础的多发性硬化症自身免疫概念：从白日梦到（治疗）途径。
Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2(Suppl 2):14599-606. doi: 10.1073/pnas.0404874101. Epub 2004 Aug 11.
4
Oral tolerance.口服耐受
Immunol Res. 2003;28(3):265-84. doi: 10.1385/IR:28:3:265.
5
Beneficial effect of co-polymer 1 on cytokine production by CD4 T cells in multiple sclerosis.共聚物1对多发性硬化症中CD4 T细胞细胞因子产生的有益作用。
Immunology. 2001 Dec;104(4):383-91. doi: 10.1046/j.1365-2567.2001.01322.x.
6
CD40L in autoimmunity and mucosally induced tolerance.自身免疫和黏膜诱导耐受中的CD40L
J Clin Invest. 2002 Jan;109(2):171-3. doi: 10.1172/JCI14930.
7
Risk-benefit assessment of glatiramer acetate in multiple sclerosis.醋酸格拉替雷治疗多发性硬化症的风险效益评估。
Drug Saf. 2001;24(13):979-90. doi: 10.2165/00002018-200124130-00005.
8
Oral tolerance, an active immunologic process mediated by multiple mechanisms.口服耐受，一种由多种机制介导的主动免疫过程。
J Clin Invest. 2000 Oct;106(8):935-7. doi: 10.1172/JCI11348.
9
Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.多发性硬化症：来自接受治疗和未接受治疗受试者的共聚物-1反应性T细胞系的比较显示细胞因子从辅助性T1细胞向辅助性T2细胞转变。
Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7452-7. doi: 10.1073/pnas.97.13.7452.
10
Induction of oral tolerance to the acetylcholine receptor for treatment of myasthenia gravis.诱导对乙酰胆碱受体的口服耐受以治疗重症肌无力。
J Clin Invest. 1999 Dec;104(12):1667-8. doi: 10.1172/JCI8775.
本文引用的文献
1
Oral tolerance: mechanisms and therapeutic applications.口服耐受：机制与治疗应用
Adv Immunol. 1999;73:153-264. doi: 10.1016/s0065-2776(08)60787-7.
2
3
Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1.口服共聚物1对实验性自身免疫性脑脊髓炎的免疫调节作用
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3842-7. doi: 10.1073/pnas.96.7.3842.
4
Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.用共聚肽-1（考帕松）治疗多发性硬化症：涉及Th1向Th2/Th3免疫偏移的机制
J Neuroimmunol. 1998 Dec 1;92(1-2):113-21. doi: 10.1016/s0165-5728(98)00191-x.
5
Control of immune pathology by regulatory T cells.调节性T细胞对免疫病理的控制。
Curr Opin Immunol. 1998 Dec;10(6):649-55. doi: 10.1016/s0952-7915(98)80084-8.
6
Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.共聚体1除了阻断主要组织相容性复合体外，还通过T细胞受体拮抗作用对抗髓鞘碱性蛋白的免疫显性表位82 - 100。
Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):634-9. doi: 10.1073/pnas.96.2.634.
7
Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1.由共聚物1诱导的Th2型T细胞系和克隆对实验性自身免疫性脑脊髓炎的旁观者抑制作用
J Neuroimmunol. 1998 Nov 2;91(1-2):135-46. doi: 10.1016/s0165-5728(98)00166-0.
8
A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance.转化生长因子-β在供体输血诱导的同种异体移植耐受中的关键作用。
J Clin Invest. 1998 Dec 1;102(11):1920-6. doi: 10.1172/JCI4221.
9
Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones.与HLA-DR蛋白结合并抑制II型胶原反应性T细胞克隆的合成氨基酸共聚物。
Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12528-31. doi: 10.1073/pnas.95.21.12528.
Zotero 插件